At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
Autologous Muscle Derived Cellsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Canadian Prospective Nonrandomized Study of Autologous Cell Therapy for Female Stress Urinary Incontinence
In Brief
A Phase 2 clinical trial evaluating Autologous Muscle Derived Cells for Stress Urinary Incontinence. Completed, enrolled 16 participants across 2 sites.
Detailed Summary
The Autologous Cell Therapy for Female SUI study is a clinical trial to determine the safety and potential effectiveness of a single dose of 200 million Cook MyoSite Autologous Muscle Derived Cells for treatment of Stress Urinary Incontinence.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStress Urinary Incontinence
CountriesCanada
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2009
Enrollment StartJun 2010
Primary CompletionSep 2012
TodayJul 2026
First PostedNov 6, 2009
Enrollment StartJun 2, 2010
Primary CompletionSep 21, 2012
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 16.7 years ago
Interventions
Autologous Muscle Derived Cellsbiological
Urethral injection of autologous muscle-derived cells